Alzheimer’s Disease

Herbal Treatments may prove valuable to treat Alzheimer’s Disease

Promising Therapeutics with Natural Bioactive Compounds for Improving Learning and Memory — A Review of Randomized Trials  

A recent review has determined that herbal treatments, such as those including flavonoids, are beneficial when attempting to prevent neurocognitive decline, commonly seen in Alzheimer’s Disease. Galantamine, quercetin, examples of two flavonoids, as well as huperzine A, bacoside A, and ginkolide B, three flavonoid-like compounds, all proved to be effective when used as a treatment for poor memory function. The authors mention the need for similar results in clinical trials but find the current data compelling evidence for future drug development. 

Highlighted in this paper is the current perception of herbal products as natural, gentle, and safe in comparison to current synthetic drugs. While herbal products are generally safer and considered to be more gentle, it is important to note that for these herbal compounds to truly be effective when treating patients they likely need modification in order to optimize their benefits. The modification would increase potency, selectivity, and pharmacokinetic abilities, as well as lessen any possible side effects. Synthetic drugs may seem frightening, particularly in light of recent illnesses and mortality associated with their abuse, but technology can also be used to optimize novel drugs and it can be efficient to do so. 



View this review (yellow link) or download:

This paper is also stored here:     http://bit.ly/2Xtu8u5    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDHerbal Treatments may prove valuable to treat Alzheimer’s Disease
read more

A systematic review of Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia

A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2IWFA8R     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDA systematic review of Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia
read more

THC Has Potential for Treating Agitation in Alzheimer’s Disease

In a crossover trial of 39 patients with Alzheimer’s disease, treatment with nabilone (a synthetic THC analog) was associated with significant improvement in agitation and, remarkably, cognition. Further studies should examine the effects of both THC and CBD in patients with Alzheimer’s disease because anxiety is common in dementia and may exacerbate agitation. 

View this review (yellow link) or download:

This paper is also stored here:   http://bit.ly/2IH2BfX      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDTHC Has Potential for Treating Agitation in Alzheimer’s Disease
read more

Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease

Researchers find 9 cannabinoids that might protect the brain against toxicities associated with aging. These non-intoxicating cannabinoids are potential drug candidates for Alzheimer’s Disease, and they might also be options for other neurodegenerative diseases, too

View this review (yellow link) or download:

This paper is also stored here:     http://bit.ly/2L9GccX    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDEfficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease
read more

Evidence for Therapeutic Benefits of Cannabidiol, Including Treatment of Ischemic Strokes

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke

Cannabidiol (CBD) has a unique therapeutic profile as it has a cannabinoid receptor-independent mechanism, limited side-effects, and patients do not seem to develop an insurmountable tolerance. Research currently focussed on the therapeutic benefits of CBD has demonstrated long-lasting neuroprotective properties against global and focal ischemic injury, such as ischemic stroke. This piece points to CBD as a major component of cannabis-based medicine as a non-psychoactive component. Further research is needed to evaluate the full clinical capabilities of CBD, including its neuroprotective effect.

View this review (yellow link) or download:

The US patent on Cannabinoids as Antioxidants and Neuroprotectants, from 1999: https://patents.google.com/patent/US6630507B1/en

This paper is also stored here:    http://bit.ly/2L0PBn3     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDEvidence for Therapeutic Benefits of Cannabidiol, Including Treatment of Ischemic Strokes
read more

More Baby Boomers Use Medical Cannabis

“More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits” – Exactly what CED Foundation brings to the industry.

Study finds that baby boomers want more education, more research, and greater openness with their health-care providers about using medical marijuana. https://on.mktw.net/2WbBqNG

Benjamin Caplan, MDMore Baby Boomers Use Medical Cannabis
read more

A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

CBD Shows Promise for Schizophrenia, Alzheimer’s, and Brain Injury Patients

A meta-analysis of previous studies investigating cannabidiol’s (CBD) potential to improve cognitive function among schizophrenia and brain injury patients offers hope to doctors and patients. In experiments on both human patients and rat models of schizophrenia, Alzheimer’s Disease, hypoxic-ischemic brain injury, hepatic encephalopathy, sepsis, pneumococcal meningitis, and cerebral malaria, the administration of CBD reduced neuroinflammation and resulting deficits in spatial learning and memory, recognition memory, and associative learning. Read more or download PDF on the CED Foundation Archive: http://bit.ly/2W1PpW8

In this same review, further investigating the effect of the non-psychoactive cannabidiol (CBD) on cognitive function suggests CBD counteracts the cognitive deficiencies induced by the psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC). Studies performed on humans and rat models demonstrated that CBD can improve episodic and recognition memory, verbal and visual learning and memory, and working memory, all skills which are usually impaired by THC content. For patients looking to reduce the aforementioned undesirable effects of cannabis, strains or products with high CBD and low THC content may be a viable solution.

Benjamin Caplan, MDA systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
read more

Entourage Effect & Alzheimer’s Disease

Research about the “entourage effect” of cannabinoids has led to potential treatments of neurodegenerative diseases such as Alzheimer’s Disease. For example, ingesting CBD along with THC not only dulls the intoxicating effects but can lead to a smoother effect rather than an experience of peaks and troughs. http://bit.ly/2W1zAPk

Benjamin Caplan, MDEntourage Effect & Alzheimer’s Disease
read more

Cannabis Components Prevent Neurodegeneration Observed in Alzheimer’s

At least 9 #cannabis components may prevent the neurodegeneration observed in #Alzheimer’s patients.

Certain cannabis components may have therapeutic potential for Alzheimer’s Disease treatment. In an analysis of eleven cannabis components, nine components protected human cells from the neurodegeneration characteristic to Alzheimer’s. Further research could shed light on the capabilities of these components with respect to Alzheimer’s treatment.

CED Foundation Google Drive:  http://bit.ly/2HHpAH0

Read Here or Download:

Benjamin Caplan, MDCannabis Components Prevent Neurodegeneration Observed in Alzheimer’s
read more